Taysha Gene Therapies Income Taxes 2020-2025 | TSHA

Taysha Gene Therapies income taxes from 2020 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.
Taysha Gene Therapies Annual Income Taxes
(Millions of US $)
2024 $0
2023 $0
2022 $0
2021 $0
2020 $0
2019 $0
Taysha Gene Therapies Quarterly Income Taxes
(Millions of US $)
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.524B $0.008B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.579B 7.44
Dr Reddy's Laboratories (RDY) India $12.154B 22.06
BridgeBio Pharma (BBIO) United States $6.126B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.800B 14.61
Bausch Health Cos (BHC) Canada $1.658B 1.21
Amphastar Pharmaceuticals (AMPH) United States $1.200B 7.99
Personalis (PSNL) United States $0.415B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00